Providers' knowledge and perception of xylazine in the unregulated drug supply: a sequential explanatory mixed-methods study.
Fentanyl
Harm Reduction
Xylazine
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
16 Aug 2024
16 Aug 2024
Historique:
received:
13
05
2024
accepted:
30
06
2024
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
15
8
2024
Statut:
epublish
Résumé
Xylazine is increasingly prevalent in the unregulated opioid supply in the United States. Exposure to this adulterant can lead to significant harm, including prolonged sedation and necrotic wounds. In the absence of literature describing healthcare providers' experiences with treating patients who have been exposed to xylazine, we aimed to explore what gaps must be addressed to improve healthcare education and best practices. From October 2023 to February 2024, we conducted a sequential explanatory mixed-methods study, with (1) a quantitative survey phase utilizing convenience sampling of healthcare providers treating patients in Connecticut and (2) a qualitative semi-structured interview phase utilizing purposive sampling of providers with experience treating patients with xylazine exposure. Summary statistics from the survey were tabulated; interview transcripts were analyzed using thematic analysis. Seventy-eight eligible healthcare providers participated in our survey. Most participants had heard of xylazine (n = 69, 95.8%) and had some knowledge about this adulterant; however, fewer reported seeing one or more patients exposed to xylazine (n = 46, 59.8%). After sampling from this subgroup, we conducted fifteen in-depth interviews. This qualitative phase revealed five themes: (1) while xylazine is novel and of concern, this is not necessarily exceptional (i.e., there are other emerging issues for patients who use drugs); (2) participants perceived that xylazine was increasingly prevalent in the drug supply, even if they were not necessarily seeing more patients with xylazine-related outcomes (XROs); (3) patients primarily presented with non-XROs, making it difficult to know when conversations about xylazine were appropriate; (4) patients with XROs may experience issues accessing healthcare; (5) providers and their patients are learning together about how to minimize XROs and reduce the sense of helplessness in the face of a novel adulterant. Xylazine-specific education for healthcare providers is currently insufficient. Improving this education, as well as resources (e.g., drug checking technologies) and data (e.g., research on prevention and treatment of XROs), is crucial to improve care for patients who use drugs.
Sections du résumé
BACKGROUND
BACKGROUND
Xylazine is increasingly prevalent in the unregulated opioid supply in the United States. Exposure to this adulterant can lead to significant harm, including prolonged sedation and necrotic wounds. In the absence of literature describing healthcare providers' experiences with treating patients who have been exposed to xylazine, we aimed to explore what gaps must be addressed to improve healthcare education and best practices.
METHODS
METHODS
From October 2023 to February 2024, we conducted a sequential explanatory mixed-methods study, with (1) a quantitative survey phase utilizing convenience sampling of healthcare providers treating patients in Connecticut and (2) a qualitative semi-structured interview phase utilizing purposive sampling of providers with experience treating patients with xylazine exposure. Summary statistics from the survey were tabulated; interview transcripts were analyzed using thematic analysis.
RESULTS
RESULTS
Seventy-eight eligible healthcare providers participated in our survey. Most participants had heard of xylazine (n = 69, 95.8%) and had some knowledge about this adulterant; however, fewer reported seeing one or more patients exposed to xylazine (n = 46, 59.8%). After sampling from this subgroup, we conducted fifteen in-depth interviews. This qualitative phase revealed five themes: (1) while xylazine is novel and of concern, this is not necessarily exceptional (i.e., there are other emerging issues for patients who use drugs); (2) participants perceived that xylazine was increasingly prevalent in the drug supply, even if they were not necessarily seeing more patients with xylazine-related outcomes (XROs); (3) patients primarily presented with non-XROs, making it difficult to know when conversations about xylazine were appropriate; (4) patients with XROs may experience issues accessing healthcare; (5) providers and their patients are learning together about how to minimize XROs and reduce the sense of helplessness in the face of a novel adulterant.
CONCLUSIONS
CONCLUSIONS
Xylazine-specific education for healthcare providers is currently insufficient. Improving this education, as well as resources (e.g., drug checking technologies) and data (e.g., research on prevention and treatment of XROs), is crucial to improve care for patients who use drugs.
Identifiants
pubmed: 39148036
doi: 10.1186/s12954-024-01052-4
pii: 10.1186/s12954-024-01052-4
doi:
Substances chimiques
Xylazine
2KFG9TP5V8
Analgesics, Opioid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
148Informations de copyright
© 2024. The Author(s).
Références
Kariisa M, O’Donnell J, Kumar S, Mattson CL, Goldberger BA. Illicitly manufactured fentanyl-involved overdose deaths with detected xylazine—United States, January 2019–June 2022. MMWR Morb Mortal Wkly Rep. 2023;72(26):721–7. https://doi.org/10.15585/mmwr.mm7226a4 .
doi: 10.15585/mmwr.mm7226a4
pubmed: 37384558
pmcid: 10328484
Kacinko SL, Mohr ALA, Logan BK, Barbieri EJ. Xylazine: pharmacology review and prevalence and drug combinations in forensic toxicology casework. J Anal Toxicol. 2022;46(8):911–7. https://doi.org/10.1093/jat/bkac049 .
doi: 10.1093/jat/bkac049
pubmed: 35770859
Ayub S, Parnia S, Poddar K, et al. Xylazine in the opioid epidemic: a systematic review of case reports and clinical implications. Cureus. 2023. https://doi.org/10.7759/cureus.36864 .
doi: 10.7759/cureus.36864
pubmed: 38161956
pmcid: 10755629
Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and overdoses: trends, concerns, and recommendations. Am J Public Health. 2022;112(8):1212–6. https://doi.org/10.2105/AJPH.2022.306881 .
doi: 10.2105/AJPH.2022.306881
pubmed: 35830662
pmcid: 9342814
Gardner EA, McGrath SA, Dowling D, Bai D. The opioid crisis: prevalence and markets of opioids. Forensic Sci Rev. 2022;34(1):43–70.
pubmed: 35105535
Wide-Ranging Online Data for Epidemiologic Research (WONDER). CDC, National Center for Health Statistics; 2021. http://wonder.cdc.gov
Ciccarone D. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183–8. https://doi.org/10.1016/j.drugpo.2019.01.010 .
doi: 10.1016/j.drugpo.2019.01.010
pubmed: 30718120
pmcid: 6675668
Ruiz-Colón K, Chavez-Arias C, Díaz-Alcalá JE, Martínez MA. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature. Forensic Sci Int. 2014;240:1–8. https://doi.org/10.1016/j.forsciint.2014.03.015 .
doi: 10.1016/j.forsciint.2014.03.015
pubmed: 24769343
Sue KL, Hawk K. Clinical considerations for the management of xylazine overdoses and xylazine-related wounds. Addiction. 2023. https://doi.org/10.1111/add.16388 .
doi: 10.1111/add.16388
pubmed: 37939387
Choi S, Irwin MR, Kiyatkin EA. Xylazine effects on opioid-induced brain hypoxia. Psychopharmacology. 2023;240(7):1561–71. https://doi.org/10.1007/s00213-023-06390-y .
doi: 10.1007/s00213-023-06390-y
pubmed: 37340247
pmcid: 10775769
Dowton A, Doernberg M, Heiman E, et al. Recognition and treatment of wounds in persons using xylazine: a case report from New Haven, Connecticut. J Addict Med. 2023. https://doi.org/10.1097/ADM.0000000000001198 .
doi: 10.1097/ADM.0000000000001198
pubmed: 37934550
O’Malley PA. Rising xylazine drug abuse in humans: a deep and lingering high with wounds, amputations, and death. Clin Nurse Spec. 2023;37(4):164–5. https://doi.org/10.1097/NUR.0000000000000758 .
doi: 10.1097/NUR.0000000000000758
pubmed: 37410559
Pennsylvania Department of Health. Xylazine and Wound Care for Healthcare Providers. 2023. https://www.health.pa.gov/topics/Documents/Opioids/Xylazine%20Provider%20Info.pdf
McFadden R, Wallace-Keeshen S, Petrillo Straub K, et al. Xylazine-associated wounds: clinical experience from a low-barrier wound care clinic in Philadelphia. J Addict Med. 2023. https://doi.org/10.1097/ADM.0000000000001245 .
doi: 10.1097/ADM.0000000000001245
pubmed: 38019592
pmcid: 10967264
Gupta R. Biden-Harris Administration Designates Fentanyl Combined with Xylazine as an Emerging Threat to the United States. 2023. https://www.whitehouse.gov/ondcp/briefing-room/2023/04/12/biden-harris-administration-designates-fentanyl-combined-with-xylazine-as-an-emerging-threat-to-the-united-states/
Torruella RA. Xylazine (veterinary sedative) use in Puerto Rico. Subst Abuse Treat Prev Policy. 2011;6(1):7. https://doi.org/10.1186/1747-597X-6-7 .
doi: 10.1186/1747-597X-6-7
pubmed: 21481268
pmcid: 3080818
Reyes JC, Negrón JL, Colón HM, et al. The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. J Urban Health. 2012;89(3):519–26. https://doi.org/10.1007/s11524-011-9662-6 .
doi: 10.1007/s11524-011-9662-6
pubmed: 22391983
pmcid: 3368046
Holt AC, Schwope DM, Le K, Schrecker JP, Heltsley R. Widespread distribution of xylazine detected throughout the United States in healthcare patient samples. J Addict Med. 2023. https://doi.org/10.1097/ADM.0000000000001132 .
doi: 10.1097/ADM.0000000000001132
pubmed: 37579111
pmcid: 10417214
DEA. PUBLIC SAFETY ALERT: DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine. https://www.dea.gov/alert/dea-reports-widespread-threat-fentanyl-mixed-xylazine
CTDPH. Connecticut Department of Public Health Drug Overdose Monthly Report. https://portal.ct.gov/-/media/DPH/Injury-and-Violence-Prevention/Opioid-Overdose-Data/Monthly-Death-Reports/2019-March-2023_Drug-Overdose-Deaths-Monthly-Report_Connecticut_updated-on-4-18-2023_Final.pdf
Quijano T, Crowell J, Eggert K, et al. Xylazine in the drug supply: emerging threats and lessons learned in areas with high levels of adulteration. Int J Drug Policy. 2023;120:104154. https://doi.org/10.1016/j.drugpo.2023.104154 .
doi: 10.1016/j.drugpo.2023.104154
pubmed: 37574646
Goddard P. Changing attitudes towards harm reduction among treatment professionals: a report from the American Midwest. Int J Drug Policy. 2003;14(3):257–60. https://doi.org/10.1016/S0955-3959(03)00075-6 .
doi: 10.1016/S0955-3959(03)00075-6
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. https://doi.org/10.1191/1478088706qp063oa .
doi: 10.1191/1478088706qp063oa
Gallanosa AG, Spyker DA, Shipe JR, Morris DL. Human xylazine overdose: a comparative review with clonidine, phenothiazines, and tricyclic antidepressants. Clin Toxicol. 1981;18(6):663–78. https://doi.org/10.3109/15563658108990293 .
doi: 10.3109/15563658108990293
pubmed: 6115734
Jones HE, Harris RJ, Downing BC, et al. Estimating the prevalence of problem drug use from drug-related mortality data. Addiction. 2020;115(12):2393–404. https://doi.org/10.1111/add.15111 .
doi: 10.1111/add.15111
pubmed: 32392631
pmcid: 7613965
Law MG, Degenhardt L, McKetin R. Methods estimating the prevalence of problem drug use. Int J Drug Policy. 2006;17(3):154–8. https://doi.org/10.1016/j.drugpo.2005.02.010 .
doi: 10.1016/j.drugpo.2005.02.010
Muncan B, Walters SM, Ezell J, Ompad DC. “They look at us like junkies”: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):53. https://doi.org/10.1186/s12954-020-00399-8 .
doi: 10.1186/s12954-020-00399-8
pubmed: 32736624
pmcid: 7393740
Fong C, Mateu-Gelabert P, Ciervo C, et al. Medical provider stigma experienced by people who use drugs (MPS-PWUD): development and validation of a scale among people who currently inject drugs in New York City. Drug Alcohol Depend. 2021;221:108589. https://doi.org/10.1016/j.drugalcdep.2021.108589 .
doi: 10.1016/j.drugalcdep.2021.108589
pubmed: 33621804
pmcid: 8029599
Biancarelli DL, Biello KB, Childs E, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80–6. https://doi.org/10.1016/j.drugalcdep.2019.01.037 .
doi: 10.1016/j.drugalcdep.2019.01.037
pubmed: 30884432
pmcid: 6521691
Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: Health services experiences among people who inject drugs. Int J Drug Policy. 2018;57:104–10. https://doi.org/10.1016/j.drugpo.2018.04.004 .
doi: 10.1016/j.drugpo.2018.04.004
pubmed: 29715589
pmcid: 5994194
Meyerson BE, Russell DM, Kichler M, Atkin T, Fox G, Coles HB. I don’t even want to go to the doctor when I get sick now: Healthcare experiences and discrimination reported by people who use drugs, Arizona 2019. Int J Drug Policy. 2021;93:103112. https://doi.org/10.1016/j.drugpo.2021.103112 .
doi: 10.1016/j.drugpo.2021.103112
pubmed: 33461838
Nolen S, Wilson T, Jacka BP, Li Y, Beaudoin FL, Marshall BDL. Prevalence and correlates of experiencing drug-related discrimination among people who use drugs presenting at emergency department at high risk of opioid overdose. Addict Behav Rep. 2023;17:100496. https://doi.org/10.1016/j.abrep.2023.100496 .
doi: 10.1016/j.abrep.2023.100496
pubmed: 37249941
pmcid: 10213175